

HETEROCYCLES, Vol. 81, No. 2, 2010, pp. 407 - 412. © The Japan Institute of Heterocyclic Chemistry
Received, 2nd October, 2009, Accepted, 22nd December, 2009, Published online, 25th December, 2009
DOI: 10.3987/COM-09-11849

¹⁵N NMR SPECTROSCOPY OF ANNULATED Δ²-PYRAZOLINES AND Δ²-1,2,4-TRIAZOLINES

Teresa Recca, Lara De Benassuti, and Giorgio Molteni*

Università degli Studi di Milano, Dipartimento di Chimica Organica e Industriale,
via Golgi 19, 20133 Milano, Italy

Abstract – Enantiopure Δ²-pyrazolines and Δ²-1,2,4-triazolines fused to the 1,4-benzodiazepine moiety, as well as Δ²-pyrazolines annulated to the 1,5-benzoxazocine moiety (racemic) or inserted in a *bis*-1,3-pyrazolophane skeleton (enantiopure) were investigated through ¹⁵N NMR spectroscopy in natural abundance. Nitrogen chemical shifts were determined by (1D)-INEPT experiments, while proton-nitrogen scalar coupling were obtained through 2D-*J*-HMBC experiments.

Due to the occurrence of nitrogen atoms in a huge number of heterocyclic rings, their study through ¹⁵N NMR spectroscopy may appear as a logical consequence in order to obtain a better knowledge of their own structures. As a matter of fact, increasing attention have been paid to this interesting topic¹ and, in particular, the chemical shifts of some ¹⁵N-enriched azoles have been investigated by ¹⁵N NMR spectroscopy.² Several efforts have also been made in studying ¹⁵N NMR of azoles in natural abundance.³ Within this field, early papers by Elguero and coworkers⁴ are concerned to simple Δ²-pyrazoline derivatives, while our recent work⁵ deals with the spectroscopic data of a series of 1-(4-substituted)phenyl-3-methoxycarbonyl-5-ethoxycarbonyl-Δ²-pyrazolines. Having firmly established the basic spectroscopic features of simple Δ²-pyrazolines within the frame of ¹⁵N NMR spectroscopy, we turned our attention to the study of annulated Δ²-pyrazolines and Δ²-1,2,4-triazolines, namely 3,3a-dihydropyrazolo[1,5-*a*][1,4]benzodiazepine-4(6*H*)-ones **1** and [1,2,4]triazolo[4,3-*a*][1,4]benzodiazepinones **2** (Figure 1), in natural abundance. These heterocyclic skeletons are particularly attracting since they belong to the class of annulated 1,4-benzodiazepines, which occupy a prominent place among drugs for the treatment of CNS disturbances.⁶ Some significant representatives are alprazolam, a common anxiolytic agent,⁷ and flumazenil⁸ which belongs to the family of cognition enhancers. Other interesting Δ²-pyrazolines annulated to the 1,5-benzoxazocine moiety (compounds **3** and **4**, racemic) or inserted in a

bis-1,3-pyrazolophane skeleton (compound **5**, enantiopure) have also been investigated.

In order to gain deeper insights about the spectroscopic features of compounds **1-5** we undertook their comprehensive ^{15}N NMR analyses.

All the substrates **1-5** submitted to ^{15}N NMR analyses (Figure 1) were synthesised *via* nitrilimine cycloaddition onto the appropriate dipolarophile. Nitrilimine intermediates were generated *in situ* by treating the corresponding hydrazonoyl chloride with silver carbonate as the basic agent, according to a procedure developed in our laboratory.⁹




Figure 1. Formulae of compounds **1-5** (pTol = *para*-tolyl).

In the cases where a chiral pendant is present a stereoselective cycloaddition took place giving mixtures of the possible enantiopure diastereoisomers.¹⁰ In the present paper we examined the spectral properties of the major diastereoisomers **1a,b**, **2a,b** and **5** in the enantiopure form, whose absolute configurations are

depicted in Figure 1 and were assigned previously on the basis of X-ray diffractometric analyses.¹¹ As far as racemic substrates **3** and **4** are concerned, their structure were assigned unambiguously by analytical and spectral data.¹²

All the experiments reported in the present paper were performed in natural abundance thus avoiding the synthesis of ¹⁵N-enriched compounds. Futhermore, the lack of ¹⁵N labeled atoms did not lead to excessive time-consuming experiments.

The ¹⁵N nuclear shielding values of compounds **1-5**, which resulted from (1D)-INEPT pulse sequences, are given in Table 1. It is known that nitrogen chemical shift (δ N) of some aromatic azoles can be affected by the solvent,¹³ however these changes occur because of explicit hydrogen bondings which are clearly absent in the present case. Hence, all experiments were performed in CDCl₃ as the solvent, while sample concentration was always 0.25 M.

Table 1. ¹⁵N chemical shifts of compounds **1-5**.^a

Compound	δ N ₁	δ N ₂	δ N ₃	δ N ₄
1a	- 224.52	- 29.60	- 241.22	—
1b	- 225.05	- 29.67	- 241.52	—
2a	- 236.61	- 101.31	- 243.87	- 274.23
2b	- 240.41	- 100.78	- 244.30	- 279.29
3	- 217.70	- 7.56	—	—
4	- 163.90	- 59.04	—	—
5	- 217.02	- 21.25	—	—

^a0.25 M in CDCl₃.

According to Table 1, the chemical shift values of N₁ and N₂ vary due to their hybridisation. It is apparent that *sp*²-hybridised N₂ falls downfield with respect to *sp*³-hybridised N₁. In other words N₂ atoms appear strongly deshielded with respect to N₁, a result which agrees with the known chemical shifts of both *sp*² and *sp*³ nitrogens of simple heterocycles.¹⁴ Some fluctuation in the N₂ chemical shift values appears from Table 1 according to their chemical environment. In particular, *sp*²-hybridised N₂ contained in the 1,2,4-triazoline ring of **2a,b** appears shielded with respect to their counterparts in the pyrazoline ring of compounds **1a,b**. Such a behaviour is hardly rationalisable on the basis of simple inductive and hybridisation effects. In fact, it may be recalled that some nitrogens experience an upfield shift due to the dominance of the increase in molecular-plane shielding over the decrease in the out-of-plane shielding.¹⁵ This latter statement can be applied to the present case since structures of compounds **1a** and **2a** provided by X-ray crystallographic analysis show better planarity for the 1,2,4-triazoline ring. Compounds **1a,b** and **2a,b** display both N₁ and N₃ or N₃ and N₄, respectively, whose chemical shifts are difficult to assign

unambiguously on the basis of the above-mentioned (1D)-INEPT experiment. In the case of such compounds 2D-HMBC experiments were required to attain this latter purpose. As far as racemic benzoxazocine-annulated pyrazoles **3** and **4** are concerned, their N_1 and N_2 chemical shifts finds a rationale in the light of the above considerations. The N_1 and N_2 chemical shifts of enantiopure *bis*-1,3-pyrazolophane **5** just match with that observed in the case of simple Δ^2 -pyrazolines.⁵

Next, we measured the $^{15}N_x$ -C-C-H scalar couplings of compounds **1-5** by means of 2D-*J*-HMBC experiments. The 3J values reported in Table 2 encompasses the range 3.3-4.2 Hz in the case of compounds **1-4**, which are consistent with literature data.¹⁶ As far as *bis*-1,3-pyrazolophane **5** is concerned, larger values of 3J were observed, namely between 6.0 and 6.2 Hz. It needs to be underlined the perfect agreement between these latter data and those previously found for simple Δ^2 -pyrazolines.⁵

Table 2. 3J values of compounds **1-5**.^a

Type of 3J	Compound						
	1a	1b	2a	2b	3	4	5
N_1 -H _A	—	—	3.8	3.5	3.6	3.4	6.0
N_1 -H _B	3.8	3.5	—	—	3.6	—	6.0
N_1 -H _X	—	—	—	—	—	—	6.1
N_1 -Me _A	—	—	3.7	—	3.9	—	—
N_2 -H _A	3.4	3.4	—	—	4.1	4.2	6.2
N_2 -H _B	3.6	3.6	—	—	4.1	—	6.2
N_3 -Me _B	5.6	3.7	3.9	3.7	—	—	—
N_4 -H _A	—	—	3.7	3.6	—	—	—
N_4 -Me _A	—	—	3.3	—	—	—	—

^aIn CDCl₃.

Novel ^{15}N NMR spectroscopic data, namely chemical shifts and scalar coupling constants, have been obtained for some enantiopure Δ^2 -pyrazolines and Δ^2 -1,2,4-triazolines fused to the 1,4-benzodiazepine moiety, as well as for racemic pyrazolo[1,5-*a*][5,1]benzoxazocines or enantiopure *bis*-1,3-pyrazolophane.

EXPERIMENTAL

Compounds **1a,b**,^{11a} **2a,b**,^{11b} **3**,^{12a} **4**,^{12b} and **5**^{11c} are known in the literature.

^{15}N NMR spectroscopic experiments.

NMR spectra were acquired on a Bruker Avance 400 MHz (40.557 MHz for ^{15}N) or on AMX 300 MHz (30.424 MHz for ^{15}N) spectrometer, both equipped with a 5 mm inverse z-gradient probe.

^{15}N chemical shifts were measured *via* (1D)-INEPT experiments, which were recorded over a range of

300 ppm with a J value of 4 Hz and a relaxation delay of 2 s.

The 2D-HMBC spectra are recorded with a J value of 4 Hz, spectral width of 300 ppm in F1 dimension, a relaxation delay of 1.5 s; data matrices of 1024 x 256 points (eight scans) were zero filled in F1 dimension to 1024 points.

$J_{\text{H-N}}$ long range were recorded by means of 2D- J -HMBC experiment of samples in CDCl_3 solution, with the following parameters: relaxation delay 4.0 s, scaling factor $\text{SF} = 23$, $J = 4$ Hz, 16 scans.

In all experiments nitromethane was used as reference of ^{15}N chemical shifts ($\delta = 0$ ppm).

ACKNOWLEDGEMENTS

Thanks are due to PUR for financial support.

REFERENCES

1. M. Witanowsky and L. Stefaniak, *Annu. Rep. NMR Spectrosc.*, **1986**, **18**, 1.
2. (a) L. Stefaniak, J. D. Roberts, M. Witanowsky, and G. A. Webb, *Org. Magn. Reson.*, **1984**, **22**, 215.
(b) T. Axenrod, C. M. Watnick, and M. J. Wieder, *Org. Magn. Reson.*, **1979**, **12**, 476.
3. (a) R. M. Claramunt, D. Sanz, C. López, J. A. Jiménez, M. L. Jimeno, J. Elguero, and A. Fruchier, *Magn. Res. Chem.*, **1997**, **35**, 35. (b) R. M. Claramunt, C. López, M. D. Santa María, D. Sanz, and J. Elguero, *Prog. NMR Spectrosc.*, **2006**, **49**, 169.
4. (a) J. Elguero, R. Faure, and J. Llinares, *Spectrosc. Lett.*, **1987**, **20**, 149. (b) I. Alkorta, J. Elguero, A. Fruchier, N. Jagerovic, and G. P. A. Yap, *J. Mol. Struct.*, **2004**, **689**, 251.
5. L. De Benassuti, T. Recca, and G. Molteni, *Tetrahedron*, **2007**, **63**, 3302.
6. J. A. Vida, 'Medicinal Chemistry'; ed. by M. W. Wolf and A. Burger, Wiley, New York, 1981, p. 787.
7. *The Merck Index*, 12th edition, ed. by S. Budavari, Merck & Co., Whitehouse Station, New Jersey, 1996.
8. W. Fröstl and L. Maître, *Pharmacopsych.*, **1989**, **22**, 54.
9. G. Molteni, *ARKIVOC*, 2007, (ii), 224.
10. G. Molteni, *Heterocycles*, **2006**, **65**, 2513.
11. (a) Compounds **1a,b**: G. Broggin, G. Casalone, L. Garanti, G. Molteni, T. Pilati, and G. Zecchi, *Tetrahedron: Asymmetry*, **1999**, **10**, 4447. (b) Compound **2a**: G. Molteni, G. Broggin, and T. Pilati, *Tetrahedron: Asymmetry*, **2002**, **13**, 2491. (c) Compound **5**: G. Broggin, G. Molteni, and T. Pilati, *Tetrahedron: Asymmetry*, **2000**, **11**, 1975.
12. (a) Compound **3**: G. Broggin, L. Bruché, L. Garanti, and G. Zecchi, *J. Chem Soc., Perkin Trans 1*, **1994**, 433. (b) Compound **4**: G. Broggin, L. Garanti, G. Molteni, and G. Zecchi, *Heterocycles*, **1994**,

[38, 1601](#).

13. M. Witanowsky, Z. Biedrzycka, W. Sicninska, and Z. Grabowsky, [J. Magn Reson., 1998, 131, 54](#).
14. A. R. Katritzky and J. M. Lagowski, '*Comprehensive Heterocyclic Chemistry*', ed. by K. T. Potts, Pergamon, Oxford, 1985, Vol. 5, Chapter 4.01, p 1.
15. C. Gatti, A. Ponti, A. Gamba, and G. Pagani, [J. Am. Chem. Soc., 1992, 114, 8634](#).
16. K. Wüthrich, '*NMR of Proteins and Nucleic Acids*', Wiley-Interscience, New York, 1986, p. 167.